ArticleNeuro-oncology advances

Olaparib in recurrent isocitrate dehydrogenase mutant high-grade glioma: A phase 2 multicenter study of the POLA Network.

Ines Esparragosa Vazquez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.